Work Package 3
Vaccine impact assessment and economic value of vaccination in ageing adults
This WP will first investigate how the full economic impact of the current management of infectious diseases (vaccine preventable, potentially vaccine preventable, non-vaccine preventable and others) in ageing adults can be measured and reported in a transparent and convincing way to optimally communicate with decision makers.
Secondly, it will analyse what the impact of new preventive interventions including vaccination could be on optimizing the management of infectious diseases in that age-group by reaching maximum gains in outcomes like QALYs but working under constraints of budget, logistics, tax payment and demographic change among others.
Notably, infectious diseases to be considered are obviously those selected within the whole VITAL-project context; i.e. influenza, pneumococcal infection, RSV (in close alignment with the RESCUE-project) and zoster, if deemed appropriate.
